Karray S, Leprince C, Merle-Beral H, Debre P, Richard Y, Galanaud P
Unité INSERM U 131, Clamart, France.
Leuk Res. 1990;14(9):809-14. doi: 10.1016/0145-2126(90)90075-k.
In this work, we studied the expression of B8.7 antigen on B lymphocytes from patients suffering from B type chronic lymphocytic leukemia (B-CLL) as well as on non Hodgkin lymphoma cells (NHL). B8.7 is an activation marker, which has been reported to be associated with the capacity of activated B cells to respond to LMW-BCGF. B lymphocytes of 11 out of 22 patients tested were B8.7 positive. With the exception of one case, LMW-BCGF is able to induce DNA synthesis by these cells in the absence of costimulation by anti-mu antibodies (anti-mu Ab). The LMW-BCGF dependent proliferation of these malignant cells is inhibited by the anti-B8.7 monoclonal antibody (anti-B8.7 MoAb), in the same line as that of normal B cells. These results obtained with monoclonal B cells confirm that the B8.7 molecule is involved in the signalling pathway of the LMW-BCGF.
在本研究中，我们研究了B8.7抗原在B型慢性淋巴细胞白血病（B-CLL）患者的B淋巴细胞以及非霍奇金淋巴瘤细胞（NHL）上的表达情况。B8.7是一种活化标志物，据报道它与活化B细胞对低分子量B细胞生长因子（LMW-BCGF）作出反应的能力相关。在检测的22例患者中，有11例患者的B淋巴细胞为B8.7阳性。除1例病例外，在无抗μ抗体（anti-mu Ab）共刺激的情况下，LMW-BCGF能够诱导这些细胞的DNA合成。与正常B细胞一样，抗B8.7单克隆抗体（anti-B8.7 MoAb）可抑制这些恶性细胞依赖LMW-BCGF的增殖。这些在单克隆B细胞上获得的结果证实，B8.7分子参与了LMW-BCGF的信号传导途径。
